{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:23:01Z","timestamp":1791260581067,"version":"4.1.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1038\/npp.2017.258","type":"journal-article","created":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T12:00:35Z","timestamp":1509537635000},"page":"1317-1323","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":114,"title":["A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Tocilizumab, An Interleukin-6 Receptor Antibody, For Residual Symptoms in Schizophrenia"],"prefix":"10.1038","volume":"43","author":[{"given":"Ragy R","family":"Girgis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Ciarleglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tse","family":"Choo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Haynes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan M","family":"Bathon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Cremers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua T","family":"Kantrowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A","family":"Lieberman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan S","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,1]]},"reference":[{"key":"BFnpp2017258_CR1","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1192\/bjp.163.4.522","volume":"163","author":"W Adams","year":"1993","unstructured":"Adams W, Kendell RE, Hare EH, Munk-Jorgensen P (1993). Epidemiological evidence that maternal influenza contributes to the aetiology of schizophrenia. An analysis of Scottish, English, and Danish data. Br J Psychiatry 163: 522\u2013534.","journal-title":"Br J Psychiatry"},{"key":"BFnpp2017258_CR2","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.schres.2006.11.016","volume":"90","author":"S Akhondzadeh","year":"2007","unstructured":"Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, Abbasi SH, Behnam B (2007). Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr Res 90: 179\u2013185.","journal-title":"Schizophr Res"},{"key":"BFnpp2017258_CR3","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1196\/annals.1423.068","volume":"1110","author":"H Amital","year":"2007","unstructured":"Amital H, Barak V, Winkler RE, Rubinow A (2007). Impact of treatment with infliximab on serum cytokine profile of patients with rheumatoid and psoriatic arthritis. Ann NY Acad Sci 1110: 649\u2013660.","journal-title":"Ann NY Acad Sci"},{"key":"BFnpp2017258_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/sj.mp.4001748","volume":"11","author":"H Ashdown","year":"2006","unstructured":"Ashdown H, Dumont Y, Ng M, Poole S, Boksa P, Luheshi GN (2006). The role of cytokines in mediating effects of prenatal infection on the fetus: implications for schizophrenia. Mol Psychiatry 11: 47\u201355.","journal-title":"Mol Psychiatry"},{"key":"BFnpp2017258_CR5","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1126\/science.1148045","volume":"318","author":"MM Behrens","year":"2007","unstructured":"Behrens MM, Ali SS, Dao DN, Lucero J, Shekhtman G, Quick KL et al (2007). Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase. Science 318: 1645\u20131647.","journal-title":"Science"},{"key":"BFnpp2017258_CR6","doi-asserted-by":"publisher","first-page":"13957","DOI":"10.1523\/JNEUROSCI.4457-08.2008","volume":"28","author":"MM Behrens","year":"2008","unstructured":"Behrens MM, Ali SS, Dugan LL (2008). Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia. J Neurosci 28: 13957\u201313966.","journal-title":"J Neurosci"},{"key":"BFnpp2017258_CR7","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/0165-5728(90)90104-U","volume":"30","author":"EN Benveniste","year":"1990","unstructured":"Benveniste EN, Sparacio SM, Norris JG, Grenett HE, Fuller GM (1990). Induction and regulation of interleukin-6 gene expression in rat astrocytes. J Neuroimmunol 30: 201\u2013212.","journal-title":"J Neuroimmunol"},{"key":"BFnpp2017258_CR8","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1176\/appi.ajp.2015.14101358","volume":"173","author":"PS Bloomfield","year":"2016","unstructured":"Bloomfield PS, Selvaraj S, Veronese M, Rizzo G, Bertoldo A, Owen DR et al (2016). Microglial activity in people at ultra high risk of psychosis and in schizophrenia: an [(11)C]PBR28 PET brain imaging study. Am J Psychiatry 173: 44\u201352.","journal-title":"Am J Psychiatry"},{"key":"BFnpp2017258_CR9","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/S0893-133X(01)00360-8","volume":"26","author":"J Borrell","year":"2002","unstructured":"Borrell J, Vela JM, Arevalo-Martin A, Molina-Holgado E, Guaza C (2002). Prenatal immune challenge disrupts sensorimotor gating in adult rats. Implications for the etiopathogenesis of schizophrenia. Neuropsychopharmacology 26: 204\u2013215.","journal-title":"Neuropsychopharmacology"},{"key":"BFnpp2017258_CR10","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1001\/archpsyc.61.8.774","volume":"61","author":"AS Brown","year":"2004","unstructured":"Brown AS, Begg MD, Gravenstein S, Schaefer CA, Wyatt RJ, Bresnahan M et al (2004). Serologic evidence of prenatal influenza in the etiology of schizophrenia. Arch Gen Psychiatry 61: 774\u2013780.","journal-title":"Arch Gen Psychiatry"},{"key":"BFnpp2017258_CR11","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1176\/appi.ajp.2009.09030361","volume":"167","author":"AS Brown","year":"2010","unstructured":"Brown AS, Derkits EJ (2010). Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatry 167: 261\u2013280.","journal-title":"Am J Psychiatry"},{"key":"BFnpp2017258_CR12","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1176\/appi.ajp.162.4.767","volume":"162","author":"AS Brown","year":"2005","unstructured":"Brown AS, Schaefer CA, Quesenberry CP Jr., Liu L, Babulas VP, Susser ES (2005). Maternal exposure to toxoplasmosis and risk of schizophrenia in adult offspring. Am J Psychiatry 162: 767\u2013773.","journal-title":"Am J Psychiatry"},{"key":"BFnpp2017258_CR13","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.biopsych.2007.09.022","volume":"63","author":"SL Buka","year":"2008","unstructured":"Buka SL, Cannon TD, Torrey EF, Yolken RH (2008). Maternal exposure to herpes simplex virus and risk of psychosis among adult offspring. Biol Psychiatry 63: 809\u2013815.","journal-title":"Biol Psychiatry"},{"key":"BFnpp2017258_CR14","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1001\/archpsyc.58.11.1032","volume":"58","author":"SL Buka","year":"2001","unstructured":"Buka SL, Tsuang MT, Torrey EF, Klebanoff MA, Bernstein D, Yolken RH (2001). Maternal infections and subsequent psychosis among offspring. Arch Gen Psychiatry 58: 1032\u20131037.","journal-title":"Arch Gen Psychiatry"},{"key":"BFnpp2017258_CR15","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1136\/ard.2010.139725","volume":"70","author":"GR Burmester","year":"2011","unstructured":"Burmester GR, Feist E, Kellner H, Braun J, Iking-Konert C, Rubbert-Roth A (2011). Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann Rheum Dis 70: 755\u2013759.","journal-title":"Ann Rheum Dis"},{"key":"BFnpp2017258_CR16","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/mp.2016.247","volume":"22","author":"K Collste","year":"2017","unstructured":"Collste K, Plaven-Sigray P, Fatouros-Bergman H, Victorsson P, Schain M, Forsberg A et al (2017). Lower levels of the glial cell marker TSPO in drug-naive first-episode psychosis patients as measured using PET and [11C]PBR28. Mol Psychiatry 22: 850\u2013856.","journal-title":"Mol Psychiatry"},{"key":"BFnpp2017258_CR17","volume-title":"Applied Longitudinal Analysis","author":"GM Fitzmaurice","year":"2004","unstructured":"Fitzmaurice GM, Laird NM, Ware JH (2004) Applied Longitudinal Analysis. Wiley: Hoboken, NJ."},{"key":"BFnpp2017258_CR18","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jpsychires.2003.10.001","volume":"38","author":"ME Fortier","year":"2004","unstructured":"Fortier ME, Joober R, Luheshi GN, Boksa P (2004). Maternal exposure to bacterial endotoxin during pregnancy enhances amphetamine-induced locomotion and startle responses in adult rat offspring. J Psychiatr Res 38: 335\u2013345.","journal-title":"J Psychiatr Res"},{"key":"BFnpp2017258_CR19","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/eji.1830190418","volume":"19","author":"K Frei","year":"1989","unstructured":"Frei K, Malipiero UV, Leist TP, Zinkernagel RM, Schwab ME, Fontana A (1989). On the cellular source and function of interleukin 6 produced in the central nervous system in viral diseases. Eur J Immunol 19: 689\u2013694.","journal-title":"Eur J Immunol"},{"key":"BFnpp2017258_CR20","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s10654-005-5081-x","volume":"20","author":"Y Ghodke","year":"2005","unstructured":"Ghodke Y, Joshi K, Chopra A, Patwardhan B (2005). HLA and disease. Eur J Epidemiol 20: 475\u2013488.","journal-title":"Eur J Epidemiol"},{"key":"BFnpp2017258_CR21","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/S0920-9964(96)00123-5","volume":"24","author":"JH Gilmore","year":"1997","unstructured":"Gilmore JH, Jarskog LF (1997). Exposure to infection and brain development: cytokines in the pathogenesis of schizophrenia. Schizophr Res 24: 365\u2013367.","journal-title":"Schizophr Res"},{"key":"BFnpp2017258_CR22","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.biopsych.2004.06.023","volume":"56","author":"MF Green","year":"2004","unstructured":"Green MF, Nuechterlein KH, Gold JM, Barch DM, Cohen J, Essock S et al (2004). Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry 56: 301\u2013307.","journal-title":"Biol Psychiatry"},{"key":"BFnpp2017258_CR23","first-page":"217","volume-title":"ECDEU Assessment Manual for Psychopharmacology: Revised, ADM 76-338","author":"W Guy","year":"1976","unstructured":"Guy W (1976) Clinical Global Impressions. In: Guy W (ed), ECDEU Assessment Manual for Psychopharmacology: Revised, ADM 76-338. Department of Health, Education, and Welfare: Washington, DC. pp 217\u2013222."},{"key":"BFnpp2017258_CR24","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1038\/npp.2017.111","volume":"42","author":"S Hafizi","year":"2017","unstructured":"Hafizi S, Da Silva T, Gerritsen C, Kiang M, Bagby RM, Prce I et al (2017a). Imaging microglial activation in individuals at clinical high risk for psychosis: an in vivo PET study with [18F]FEPPA. Neuropsychopharmacology 42: 2474\u20132481.","journal-title":"Neuropsychopharmacology"},{"key":"BFnpp2017258_CR25","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1176\/appi.ajp.2016.16020171","volume":"174","author":"S Hafizi","year":"2017","unstructured":"Hafizi S, Tseng HH, Rao N, Selvanathan T, Kenk M, Bazinet RP et al (2017b). Imaging microglial activation in untreated first-episode psychosis: a PET study with [18F]FEPPA. Am J Psychiatry 174: 118\u2013124.","journal-title":"Am J Psychiatry"},{"key":"BFnpp2017258_CR26","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/j.jpsychires.2011.04.009","volume":"45","author":"H Himmerich","year":"2011","unstructured":"Himmerich H, Schonherr J, Fulda S, Sheldrick AJ, Bauer K, Sack U (2011). Impact of antipsychotics on cytokine production in-vitro. J Psychiatr Res 45: 1358\u20131365.","journal-title":"J Psychiatr Res"},{"key":"BFnpp2017258_CR27","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/0166-2236(95)80029-2","volume":"18","author":"SJ Hopkins","year":"1995","unstructured":"Hopkins SJ, Rothwell NJ (1995). Cytokines and the nervous system. I: Expression and recognition. Trends Neurosci 18: 83\u201388.","journal-title":"Trends Neurosci"},{"key":"BFnpp2017258_CR28","doi-asserted-by":"publisher","first-page":"3375","DOI":"10.1172\/JCI57158","volume":"121","author":"SA Jones","year":"2011","unstructured":"Jones SA, Scheller J, Rose-John S (2011). Therapeutic strategies for the clinical blockade of IL-6\/gp130 signaling. J Clin Invest 121: 3375\u20133383.","journal-title":"J Clin Invest"},{"key":"BFnpp2017258_CR29","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1093\/schbul\/16.3.537","volume":"16","author":"SR Kay","year":"1990","unstructured":"Kay SR, Sevy S (1990). Pyramidical model of schizophrenia. Schizophr Bull 16: 537\u2013545.","journal-title":"Schizophr Bull"},{"key":"BFnpp2017258_CR30","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1093\/schbul\/sbn110","volume":"36","author":"AS Kemp","year":"2010","unstructured":"Kemp AS, Schooler NR, Kalali AH, Alphs L, Anand R, Awad G et al (2010). What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it? Schizophr Bull 36: 504\u2013509.","journal-title":"Schizophr Bull"},{"key":"BFnpp2017258_CR31","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1093\/schbul\/sbu157","volume":"41","author":"M Kenk","year":"2015","unstructured":"Kenk M, Selvanathan T, Rao N, Suridjan I, Rusjan P, Remington G et al (2015). Imaging neuroinflammation in gray and white matter in schizophrenia: an in-vivo PET study with [18F]-FEPPA. Schizophr Bull 41: 85\u201393.","journal-title":"Schizophr Bull"},{"key":"BFnpp2017258_CR32","first-page":"107","volume":"24","author":"BJ Kinon","year":"2011","unstructured":"Kinon BJ, Potts AJ, Watson SB (2011). Placebo response in clinical trials with schizophrenia patients. Curr Opin Psychiatry 24: 107\u2013113.","journal-title":"Curr Opin Psychiatry"},{"key":"BFnpp2017258_CR33","doi-asserted-by":"publisher","first-page":"520","DOI":"10.4088\/JCP.09m05117yel","volume":"71","author":"W Laan","year":"2010","unstructured":"Laan W, Grobbee DE, Selten JP, Heijnen CJ, Kahn RS, Burger H (2010). Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 71: 520\u2013527.","journal-title":"J Clin Psychiatry"},{"key":"BFnpp2017258_CR34","first-page":"343","volume":"22","author":"J Levine","year":"1986","unstructured":"Levine J, Schooler NR (1986). SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull 22: 343\u2013381.","journal-title":"Psychopharmacol Bull"},{"key":"BFnpp2017258_CR35","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/nrn1648","volume":"6","author":"DA Lewis","year":"2005","unstructured":"Lewis DA, Hashimoto T, Volk DW (2005). Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 6: 312\u2013324.","journal-title":"Nat Rev Neurosci"},{"key":"BFnpp2017258_CR36","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.schres.2004.09.010","volume":"72","author":"SR Marder","year":"2004","unstructured":"Marder SR, Fenton W (2004). Measurement and treatment research to improve cognition in schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophr Res 72: 5\u20139.","journal-title":"Schizophr Res"},{"key":"BFnpp2017258_CR37","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s11926-012-0276-0","volume":"14","author":"CA McBurney","year":"2012","unstructured":"McBurney CA, Vina ER (2012). Racial and ethnic disparities in rheumatoid arthritis. Curr Rheumatol Rep 14: 463\u2013471.","journal-title":"Curr Rheumatol Rep"},{"key":"BFnpp2017258_CR38","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","volume":"70","author":"BJ Miller","year":"2011","unstructured":"Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B (2011). Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 70: 663\u2013671.","journal-title":"Biol Psychiatry"},{"key":"BFnpp2017258_CR39","doi-asserted-by":"publisher","first-page":"275","DOI":"10.4088\/JCP.15l09920","volume":"77","author":"BJ Miller","year":"2016","unstructured":"Miller BJ, Dias JK, Lemos HP, Buckley PF (2016). An open-label, pilot trial of adjunctive tocilizumab in schizophrenia. J Clin Psychiatry 77: 275\u2013276.","journal-title":"J Clin Psychiatry"},{"key":"BFnpp2017258_CR40","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.biopsych.2006.05.024","volume":"61","author":"PB Mortensen","year":"2007","unstructured":"Mortensen PB, Norgaard-Pedersen B, Waltoft BL, Sorensen TL, Hougaard D, Torrey EF et al (2007). Toxoplasma gondii as a risk factor for early-onset schizophrenia: analysis of filter paper blood samples obtained at birth. Biol Psychiatry 61: 688\u2013693.","journal-title":"Biol Psychiatry"},{"key":"BFnpp2017258_CR41","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.schres.2010.04.015","volume":"121","author":"N Muller","year":"2010","unstructured":"Muller N, Krause D, Dehning S, Musil R, Schennach-Wolff R, Obermeier M et al (2010). Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr Res 121: 118\u2013124.","journal-title":"Schizophr Res"},{"key":"BFnpp2017258_CR42","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1176\/appi.ajp.159.6.1029","volume":"159","author":"N Muller","year":"2002","unstructured":"Muller N, Riedel M, Scheppach C, Brandstatter B, Sokullu S, Krampe K et al (2002). Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry 159: 1029\u20131034.","journal-title":"Am J Psychiatry"},{"key":"BFnpp2017258_CR43","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1093\/schbul\/sbt070","volume":"39","author":"M Nitta","year":"2013","unstructured":"Nitta M, Kishimoto T, Muller N, Weiser M, Davidson M, Kane JM et al (2013). Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. Schizophr Bull 39: 1230\u20131241.","journal-title":"Schizophr Bull"},{"key":"BFnpp2017258_CR44","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/0140-6736(91)92919-S","volume":"337","author":"E O'Callaghan","year":"1991","unstructured":"O'Callaghan E, Sham P, Takei N, Glover G, Murray RM (1991). Schizophrenia after prenatal exposure to 1957 A2 influenza epidemic. Lancet 337: 1248\u20131250.","journal-title":"Lancet"},{"key":"BFnpp2017258_CR45","doi-asserted-by":"publisher","first-page":"e41623","DOI":"10.1371\/journal.pone.0041623","volume":"7","author":"A Patel","year":"2012","unstructured":"Patel A, Zhu Y, Kuzhikandathil EV, Banks WA, Siegel A, Zalcman SS (2012). Soluble interleukin-6 receptor induces motor stereotypies and co-localizes with gp130 in regions linked to cortico-striato-thalamo-cortical circuits. PLoS ONE 7: e41623.","journal-title":"PLoS ONE"},{"key":"BFnpp2017258_CR46","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.bbr.2008.12.016","volume":"204","author":"PH Patterson","year":"2009","unstructured":"Patterson PH (2009). Immune involvement in schizophrenia and autism: etiology, pathology and animal models. Behav Brain Res 204: 313\u2013321.","journal-title":"Behav Brain Res"},{"key":"BFnpp2017258_CR47","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","volume":"168","author":"K Posner","year":"2011","unstructured":"Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA et al (2011). The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 168: 1266\u20131277.","journal-title":"Am J Psychiatry"},{"key":"BFnpp2017258_CR48","unstructured":"Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF et al (2012). A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. Arch Gen Psychiatry 1\u201311."},{"key":"BFnpp2017258_CR49","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1176\/appi.ps.55.9.1052","volume":"55","author":"N Revheim","year":"2004","unstructured":"Revheim N, Medalia A (2004). The independent living scales as a measure of functional outcome for schizophrenia. Psychiatr Serv 55: 1052\u20131054.","journal-title":"Psychiatr Serv"},{"key":"BFnpp2017258_CR50","first-page":"R139","volume":"274","author":"TM Reyes","year":"1998","unstructured":"Reyes TM, Coe CL (1998). The proinflammatory cytokine network: interactions in the CNS and blood of rhesus monkeys. Am J Physiol 274: R139\u2013R144.","journal-title":"Am J Physiol"},{"key":"BFnpp2017258_CR51","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/0166-2236(95)93890-A","volume":"18","author":"NJ Rothwell","year":"1995","unstructured":"Rothwell NJ, Hopkins SJ (1995). Cytokines and the nervous system II: actions and mechanisms of action. Trends Neurosci 18: 130\u2013136.","journal-title":"Trends Neurosci"},{"key":"BFnpp2017258_CR52","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1001\/jamapsychiatry.2014.1319","volume":"71","author":"BR Rutherford","year":"2014","unstructured":"Rutherford BR, Pott E, Tandler JM, Wall MM, Roose SP, Lieberman JA (2014). Placebo response in antipsychotic clinical trials: a meta-analysis. JAMA Psychiatry 71: 1409\u20131421.","journal-title":"JAMA Psychiatry"},{"key":"BFnpp2017258_CR53","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1113\/jphysiol.2006.111260","volume":"575","author":"AM Samuelsson","year":"2006","unstructured":"Samuelsson AM, Alexanderson C, Molne J, Haraldsson B, Hansell P, Holmang A (2006). Prenatal exposure to interleukin-6 results in hypertension and alterations in the renin-angiotensin system of the rat. J Physiol 575: 855\u2013867.","journal-title":"J Physiol"},{"key":"BFnpp2017258_CR54","doi-asserted-by":"crossref","first-page":"139","DOI":"10.31887\/DCNS.2003.5.2\/mschwarz","volume":"5","author":"MJ Schwarz","year":"2003","unstructured":"Schwarz MJ (2003). Cytokines, neurophysiology, neuropsychology, and psychiatric symptoms. Dialog Clin Neurosci 5: 139\u2013153.","journal-title":"Dialog Clin Neurosci"},{"issue":"Suppl","key":"BFnpp2017258_CR55","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","volume":"212","author":"GM Simpson","year":"1970","unstructured":"Simpson GM, Angus JWS (1970). A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212 (Suppl): 11\u201319.","journal-title":"Acta Psychiatr Scand"},{"key":"BFnpp2017258_CR56","doi-asserted-by":"publisher","first-page":"10695","DOI":"10.1523\/JNEUROSCI.2178-07.2007","volume":"27","author":"SE Smith","year":"2007","unstructured":"Smith SE, Li J, Garbett K, Mirnics K, Patterson PH (2007). Maternal immune activation alters fetal brain development through interleukin-6. J Neurosci 27: 10695\u201310702.","journal-title":"J Neurosci"},{"key":"BFnpp2017258_CR57","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60784-3","volume":"370","author":"JS Smolen","year":"2007","unstructured":"Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P (2007). New therapies for treatment of rheumatoid arthritis. Lancet 370: 1861\u20131874.","journal-title":"Lancet"},{"key":"BFnpp2017258_CR58","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1093\/rheumatology\/ker338","volume":"51","author":"HL Wright","year":"2012","unstructured":"Wright HL, Bucknall RC, Moots RJ, Edwards SW (2012). Analysis of SF and plasma cytokines provides insights into the mechanisms of inflammatory arthritis and may predict response to therapy. Rheumatology (Oxford) 51: 451\u2013459.","journal-title":"Rheumatology (Oxford)"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/npp2017258.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/npp2017258","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/npp.2017.258","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/npp2017258.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T23:59:01Z","timestamp":1684454341000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/npp2017258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,1]]},"references-count":58,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["BFnpp2017258"],"URL":"https:\/\/doi.org\/10.1038\/npp.2017.258","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,1]]},"assertion":[{"value":"30 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}